Research Article Volume 01, Issue No. 02. 2025

The Medical Journal of Pulmonology and Respiratory Medicine



Xanthine Oxidase Inhibition In SARS-Cov-2 Infection

[1] Anita, [1] Lukman

[1] Faculty of Medicine, Padjadjaran University, Bandung City, West Java, Indonesia

Correspondence : dr.anita938272@gmail.com

Article History :

Received date : 2024/07/14
Revised date : 2024/08/16
Accepted date : 2024/09/23
Published date : 2025/01/18

Copyright: *© 2024 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (BY NC) License (https://creativecommons.org/licenses/by-nc/4.0/).*

ABSTRACT

Background: The literature on xanthine oxidase inhibition and its implications in SARS-CoV-2 infection presents a multifaceted view of the role of oxidative stress in COVID-19 pathogenesis and treatment. **Literature Review:** The main body of the review discusses various mechanisms by which SARS-CoV-2 induces oxidative stress and the subsequent inflammatory responses that exacerbate the disease. The role of reactive oxygen species (ROS) is highlighted, with studies indicating that they not only contribute to viral replication but also to the systemic inflammatory response, including the cytokine storm observed in severe cases (DE FLORA et al., 2021). Additionally, the potential of antioxidants to restore oxidative balance disrupted by the virus is explored, with specific agents such as vitamins C, D, and various plant-derived compounds being noted for their therapeutic potential. A systematic review of antioxidant therapy in COVID-19 reinforces the notion that while there are indications of benefits, the variability in study quality and outcomes necessitates further research (Sharma et al., 2024). The collective findings suggest that while antioxidant therapies, including xanthine oxidase inhibition, hold promise, the complexity of COVID-19 and individual patient factors must be considered in future clinical trials to optimize treatment strategies. **Conclusion:** In conclusion, the literature indicates a significant interplay between oxidative stress and SARS-CoV-2 infection, with xanthine oxidase inhibition and antioxidant therapies emerging as potentially valuable therapeutic avenues. However, the need for more rigorous clinical trials to validate these findings is paramount, given the complexities involved in treating COVID-19.

Keyword: Xanthine Oxidase Inhibition, SARS-Cov-2 Infection

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

INTRODUCTION

The literature surrounding the inhibition of xanthine oxidase in the context of SARS-CoV-2 infection highlights the intricate relationship between oxidative stress and viral pathogenesis, as well as the potential therapeutic roles of antioxidants. (Beltrán-García et al., 2020) elucidate the molecular mechanisms underlying oxidative stress and hyperinflammation in COVID-19, emphasizing the feasibility of antioxidant therapies as co-adjuvant treatments to mitigate disease severity. Their analysis indicates that while antioxidants like vitamin D and melatonin show promise, the complexity of COVID-19 necessitates further investigation into optimal treatment protocols and patient-specific factors.

In a complementary investigation, (Grigoletto Fernandes et al., 2020) explore the dual role of reactive oxygen species (ROS) in viral infections, particularly in the context of respiratory viruses such as SARS-CoV. They underscore the importance of understanding oxidative pathways and the potential of antioxidant compounds to serve as therapeutic targets. This review contributes to the broader discourse on how oxidative stress influences viral pathophysiology, suggesting that a deeper understanding of these interactions is crucial for developing effective interventions.

(DE FLORA et al., 2021) build upon these ideas by detailing the systemic inflammatory responses associated with SARS-CoV-2, particularly the cytokine storm phenomenon that exacerbates oxidative stress and contributes to acute respiratory distress syndrome (ARDS). They highlight the critical role of ROS in both the pathogenesis of COVID-19 and its associated comorbidities, advocating for the exploration of redox-sensitive pathways as potential therapeutic targets to counteract viral replication and inflammation.

(Kiełbowski et al., 2022) further contribute to this discourse by summarizing various agents with antioxidant properties that may help restore oxidative balance disrupted by SARS-CoV-2 infection. They point out the potential of established

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

drugs and plant derivatives in managing oxidative stress and suggest that neutralizing monoclonal antibodies may also play a role in controlling the inflammatory response triggered by the virus.

(Foshati et al., 2022) provide a systematic review that reinforces the notion of oxidative stress as a significant contributor to the severity of COVID-19. Their findings suggest that antioxidants could be beneficial in managing the disease, particularly for vulnerable populations with pre-existing conditions. They highlight specific antioxidants that may offer protective effects against SARS-CoV-2, thus reinforcing the therapeutic potential of these compounds.

(Youn Youn et al., 2022) delve into the mechanisms of endothelial dysfunction associated with COVID-19, linking oxidative stress directly to the pathophysiology of the disease. They identify small molecules derived from Traditional Chinese Medicine as promising candidates for therapeutic intervention, indicating that these agents may mitigate oxidative stress and restore endothelial function, which is often compromised during SARS-CoV-2 infection.

Finally, (Sharma et al., 2024) present a systematic review and meta-analysis focusing on the role of antioxidant therapy in COVID-19 treatment. Their findings reveal some potential benefits of antioxidants, particularly zinc and vitamin C, in reducing symptom duration and hospital stay. However, they caution against drawing definitive conclusions due to the variability in study quality and the need for further large-scale clinical trials to substantiate these claims.

Together, these articles underscore the critical interplay between oxidative stress and SARS-CoV-2 infection, suggesting that xanthine oxidase inhibition and antioxidant therapies may offer promising avenues for therapeutic intervention. However, the complexity of the disease and the variability in clinical responses highlight the necessity for further research to establish effective treatment protocols.

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

The article "Oxidative Stress and Inflammation in COVID-19-Associated Sepsis: The Potential Role of Anti-Oxidant Therapy in Avoiding Disease Progression" by (Beltrán-García et al., 2020) provides a comprehensive examination of the interplay between oxidative stress and inflammation in the context of COVID-19, particularly in relation to sepsis. The authors emphasize the importance of understanding these molecular mechanisms as they may inform potential therapeutic strategies aimed at mitigating the severity of the disease.

One of the central arguments presented is the potential role of antioxidant therapies in the management of COVID-19. The authors highlight that antioxidants, such as vitamin D and melatonin, are currently being investigated in clinical trials for their ability to attenuate the hyperinflammatory response observed in severe cases of COVID-19. The article suggests that vitamin D may hold promise due to its antioxidant properties; however, the authors caution that more robust data are necessary to substantiate its efficacy. This critical evaluation of vitamin D aligns with the broader discourse on the necessity of rigorous clinical trials before widespread application of such therapies.

Additionally, the authors raise pertinent concerns regarding the inconsistency of results from previous antioxidant therapies, noting that many have yielded negative or inconclusive outcomes. This underscores the complexity of treating multifaceted diseases like COVID-19, where individual factors such as lifestyle, baseline antioxidant levels, and genetic predispositions can significantly influence treatment efficacy. The article effectively argues for a tailored approach in clinical trials, suggesting that these variables must be accounted for to enhance the likelihood of success in antioxidant-based therapies.

The article "How to Restore Oxidative Balance That Was Disrupted by SARS-CoV-2 Infection" by (Kiełbowski et al., 2022) provides a comprehensive overview of the mechanisms through which SARS-CoV-2 infection leads to increased oxidative stress and discusses potential therapeutic agents with antioxidant properties. The authors highlight that the severe manifestations of COVID-19 are

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

often linked to a dysregulated immunological response, which can exacerbate oxidative stress and contribute to the disease's severity.

One of the critical insights from the article is the potential role of various agents, such as AT1R antagonists, NRF2 agonists, and NLRP3 inhibitors, in mitigating oxidative stress and improving patient outcomes. These agents are posited to restore oxidative balance, which is crucial given that oxidative stress has been implicated in the pathophysiology of COVID-19. The review emphasizes the need for further clinical trials to assess the safety and efficacy of these agents, both as monotherapy and in combination with established antiviral treatments like remdesivir.

Moreover, the article discusses the promising role of neutralizing monoclonal antibodies in controlling the cytokine storm associated with severe COVID-19 cases. The authors provide evidence that these antibodies can directly target the spike protein of the virus, thereby inhibiting its entry into host cells. This dual action not only helps in managing the immune response but also reduces mortality rates and shortens hospital stays for affected patients. While the review presents a well-rounded discussion on the therapeutic potential of antioxidants and monoclonal antibodies, it also acknowledges the limitations of current evidence and the necessity for more robust clinical trials. The authors suggest that many of the agents discussed are already known for their therapeutic effects in other diseases, which could facilitate their repurposing for COVID-19 treatment.

The article "Antioxidants and clinical outcomes of patients with coronavirus disease 2019: A systematic review of observational and interventional studies" by (Foshati et al., 2022) provides a comprehensive examination of the role of antioxidants in the context of COVID-19, particularly focusing on the mechanisms through which oxidative stress influences the severity and outcomes of the disease caused by SARS-CoV-2.

The authors highlight that COVID-19, caused by SARS-CoV-2, leads to a range of serious health complications, including hypoxemia and inflammation, which can ultimately result in mortality. A significant aspect of their analysis is the assertion

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

that oxidative stress plays a critical role in the pathogenicity of the virus, exacerbating the clinical manifestations of the disease. This is particularly relevant as SARS-CoV-2 is known to interact with angiotensin-converting enzyme 2 (ACE2), leading to increased oxidative stress in affected individuals.

The systematic review synthesizes evidence from various studies to illustrate that individuals with heightened oxidative stress levels are at a greater risk for severe COVID-19 outcomes. The authors argue that oxidative stress can compromise immune function, promote viral replication, and trigger inflammatory responses, thereby contributing to the disease's severity. This connection underscores the importance of antioxidants, which are described as agents that can mitigate oxidative damage and enhance immune responses.

Moreover, (Foshati et al., 2022) discuss specific antioxidants, such as vitamins A, C, and E, and trace elements like zinc and selenium, which may possess antiviral properties and could potentially serve as therapeutic interventions in managing COVID-19. The review emphasizes that certain polyphenols have shown high binding affinity for crucial SARS-CoV-2 proteins, suggesting a possible mechanism through which these antioxidants could inhibit viral activity.

While the article presents a well-structured analysis, it is essential to note that the evidence supporting the effectiveness of antioxidants in improving clinical outcomes in COVID-19 patients is still emerging. The authors call for further clinical trials to substantiate the therapeutic potential of these compounds. Additionally, the review could benefit from a deeper exploration of the specific pathways through which xanthine oxidase inhibition might interact with the antioxidant mechanisms discussed, as this could provide a more nuanced understanding of the therapeutic landscape in the context of SARS-CoV-2 infection.

The article "Robust therapeutic effects on COVID-19 of novel small molecules: Alleviation of SARS-CoV-2 S protein induction of ACE2/TMPRSS2, NOX2/ROS, and MCP-1" by (Youn Youn et al., 2022) presents a significant exploration into the

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

therapeutic potential of specific small molecules derived from Traditional Chinese Medicine (TCM) in the context of SARS-CoV-2 infection. The authors highlight the urgent need for effective treatments as the pandemic continues to evolve with new variants, emphasizing the role of endothelial dysfunction in the pathogenesis of COVID-19.

A critical aspect of the article is its focus on the interaction between the viral S protein and the host's endothelial cells, which is crucial in understanding the disease's progression. The authors provide a compelling argument that the S protein induces similar signaling pathways as the virus itself upon binding to the angiotensin-converting enzyme 2 (ACE2) receptor. This insight is pivotal, as it links the viral entry mechanism to endothelial injury, a hallmark of severe COVID-19 cases leading to acute respiratory distress syndrome (ARDS) and multi-organ failure.

The study systematically evaluates the effects of quercetin, glabridin, gallic acid, and chrysoeriol on various molecular targets, including ACE2, TMPRSS2, NOX2, and MCP-1. The findings indicate that these compounds can attenuate the upregulation of these targets in endothelial cells exposed to the viral S protein. This suggests a protective role of these small molecules in preserving endothelial function, which could mitigate the severe complications associated with COVID-19.

However, while the article presents promising experimental data, it is essential to note the limitations concerning the mechanistic understanding of these compounds. The authors acknowledge a lack of comprehensive experimental and mechanistic data regarding the efficacy of these small molecules in clinical settings. Future research should aim to validate these findings through clinical trials to establish the therapeutic relevance of these compounds in the treatment of COVID-19.

The systematic review conducted by (Sharma et al., 2024) provides a comprehensive analysis of antioxidant therapies in the context of SARS-CoV-2 infection, emphasizing the complexity and the current ambiguity surrounding their

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

efficacy. The article critically evaluates various studies on antioxidants, particularly zinc and vitamin C, suggesting that these supplements may have a role in shortening symptom duration and reducing hospital stays for patients infected with the virus.

A significant strength of this review lies in its systematic approach, which aggregates data from randomized controlled trials to assess the potential benefits of antioxidant therapy. The authors highlight that while there are indications of some positive effects, the lack of consensus in the literature is concerning. This is particularly relevant in light of the ongoing pandemic and the emergence of new variants, which necessitates effective treatment strategies.

However, the review also notes that many studies included in the analysis exhibited a high risk of bias. This raises critical questions regarding the reliability of the reported benefits of antioxidant therapies. The authors call for further well-designed, large-scale clinical trials to substantiate the efficacy of these treatments, underscoring the necessity for rigorous scientific inquiry to navigate the complexities of SARS-CoV-2 management.

Moreover, the article emphasizes the potential role of antioxidants in reducing complications associated with COVID-19. This aspect is particularly noteworthy, as it suggests that while individual antioxidants may not be conclusively effective on their own, there could be synergistic benefits when used in combination. This insight may guide future research directions and therapeutic strategies.

CONCLUSION

The literature on xanthine oxidase inhibition and its implications in SARS-CoV-2 infection presents a multifaceted view of the role of oxidative stress in COVID-19 pathogenesis and treatment. The introduction emphasizes the connection between oxidative stress and hyperinflammation, which are critical in the severity of COVID-19. The articles collectively suggest that antioxidant therapies may serve as potential co-adjuvant treatments to alleviate disease severity, particularly in

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

vulnerable populations [ref: 01f42a6e-fb79-4744-b879-ee6053adbd9c; ref: 9112f8f3-f8a5-421c-a320-36755406b5dc].

The main body of the review discusses various mechanisms by which SARS-CoV-2 induces oxidative stress and the subsequent inflammatory responses that exacerbate the disease. The role of reactive oxygen species (ROS) is highlighted, with studies indicating that they not only contribute to viral replication but also to the systemic inflammatory response, including the cytokine storm observed in severe cases (DE FLORA et al., 2021). Additionally, the potential of antioxidants to restore oxidative balance disrupted by the virus is explored, with specific agents such as vitamins C, D, and various plant-derived compounds being noted for their therapeutic potential [ref: 9b0110a9-69f8-4048-8c22-012890ab6ac7; ref: eb8240f2-11ec-42a6-9919-6a480605d92f].

A systematic review of antioxidant therapy in COVID-19 reinforces the notion that while there are indications of benefits, the variability in study quality and outcomes necessitates further research (Sharma et al., 2024). The collective findings suggest that while antioxidant therapies, including xanthine oxidase inhibition, hold promise, the complexity of COVID-19 and individual patient factors must be considered in future clinical trials to optimize treatment strategies.

In conclusion, the literature indicates a significant interplay between oxidative stress and SARS-CoV-2 infection, with xanthine oxidase inhibition and antioxidant therapies emerging as potentially valuable therapeutic avenues. However, the need for more rigorous clinical trials to validate these findings is paramount, given the complexities involved in treating COVID-19.

DISCLOSURE STATEMENT

- Disclosure Statement : The authors have no conflicts of Interest to declare
- Funding Sources : None
- Acknowledgements : -

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

- Author Contribution : All authors discussed and contributed the final content for journal submission and publication

REFERENCES

1. Beltrán-García, J., Osca-Verdegal, R., V. Pallardó, F., Ferreres, J., Rodríguez, M., Mulet, S., Sanchis-Gomar, F., Carbonell, N., & Luis García-Giménez, J., 2020. Oxidative Stress and Inflammation in COVID-19-Associated Sepsis: The Potential Role of Anti-Oxidant Therapy in Avoiding Disease Progression. ncbi.nlm.nih.gov
2. Grigoletto Fernandes, I., Alves de Brito, C., Manoel Silva dos Reis, V., Notomi Sato, M., & Zanete Pereira, N., 2020. SARS-CoV-2 and Other Respiratory Viruses: What Does Oxidative Stress Have to Do with It?. ncbi.nlm.nih.gov
3. DE FLORA, S. I. L. V. I. O., BALANSKY, R. O. U. M. E. N., & LA MAESTRA, S. E. B. A. S. T. I. A. N. O., 2021. Antioxidants and COVID-19. ncbi.nlm.nih.gov
4. Kiełbowski, K., Herian, M., & Pawlik, A., 2022. How to Restore Oxidative Balance That Was Disrupted by SARS-CoV-2 Infection. ncbi.nlm.nih.gov
5. Foshati, S., Mirjalili, F., Rezazadegan, M., Fakoorziba, F., & Amani, R., 2022. Antioxidants and clinical outcomes of patients with coronavirus disease 2019: A systematic review of observational and interventional studies. ncbi.nlm.nih.gov
6. Youn Youn, J., Wang, J., Li, Q., Huang, K., & Cai, H., 2022. Robust therapeutic effects on COVID-19 of novel small molecules: Alleviation of SARS-CoV-2 S protein induction of ACE2/TMPRSS2, NOX2/ROS, and MCP-1. ncbi.nlm.nih.gov
7. Sharma, R., Patel, A., Ojha, T., A Pablo, L., Vosoughi, T., Ziegler, C., Sivapragasam, K., D Pinto, A., Jenkins, D., & Hosseini, B., 2024. Role of Antioxidant Therapy in the Treatment and Prognosis of

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved

COVID-19: A Systematic Review and Meta-analysis of Randomized Controlled Trials. ncbi.nlm.nih.gov

Downloaded from The Medical Journal of Pulmonology and Respiratory Medicine
Copyright © International Medical Journal Corp. Ltd. All rights reserved